LINC02022

Across TCGA pan-cancer cohorts, LINC02022 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LINC02022’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC02022 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC02022 is over-expressed in tumor, although a few such as BRCA and PRAD show the opposite, repressed pattern.

BRCA, HNSC, and KIRP are the cancer types where LINC02022 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02022 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	II,III,IV	−0.204	<.001	4	view →
HNSC	Female	II,III,IV	+0.051	.016	3	view →
KIRP	All	III,IV	+0.050	.040	2	view →
PRAD	All	All	−0.033	.033	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

LINC02022–BRCA

Open the BRCA breakdown →